SKELID Drug Patent Profile

Which patents cover Skelid, and when can generic versions of Skelid launch?

Skelid is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in SKELID is tiludronate disodium. There is one drug master file entry for this compound. Additional details are available on the tiludronate disodium profile page.

Summary for SKELID

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	1
DailyMed Link:	SKELID at DailyMed

Recent Clinical Trials for SKELID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique - Hôpitaux de Paris	Phase 3

See all SKELID clinical trials

US Patents and Regulatory Information for SKELID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	SKELID	tiludronate disodium	TABLET;ORAL	020707-001	Mar 7, 1997		DISCN	Yes	No

Expired US Patents for SKELID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	SKELID	tiludronate disodium	TABLET;ORAL	020707-001	Mar 7, 1997	4,876,248
Sanofi Aventis Us	SKELID	tiludronate disodium	TABLET;ORAL	020707-001	Mar 7, 1997	4,980,171

International Patents for SKELID

See the table below for patents covering SKELID around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	77122	PROCEDE DE PREPARATION DE DERIVES DE L'ACIDE METHYLENEDIPHOSPHONIQUE
Philippines	26647	Pharmaceutical composition for oral administration based on a diphosphonic acid derivative
Ireland	831716
Australia	618796
Spain	8403923
Singapore	18588

Supplementary Protection Certificates for SKELID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0100718	SPC/GB96/027	United Kingdom
0100718	96C0006	Belgium		PRODUCT NAME: TILUDRONATE DISODIQUE EXPRIME EN ACIDE TILUDRONIQUE; NAT. REGISTRATION NO/DATE: 201 IS 106 F 3 19950907; FIRST REGISTRATION: LI 53014 19950220

Market Dynamics and Financial Trajectory for SKELID (denosumab)

Last updated: February 20, 2026

What is SKELID?

SKELID is a pharmaceutical drug containing denosumab, marketed by Novartis. It is approved for use in the prevention of osteoporotic fractures in postmenopausal women with a high risk of fracture. In the United States, SKELID is indicated for treatment of osteoporosis as adjunct therapy to calcium and vitamin D in women at high risk for fracture.

Market Size and Penetration

Global Osteoporosis Drug Market

The osteoporosis drug market was valued at approximately $11.5 billion in 2022 and is projected to reach $15.3 billion by 2027, with a compound annual growth rate (CAGR) of 5.8% (Fortune Business Insights, 2022).

Denosumab Segment

Denosumab accounts for about 40% of this market, driven by its efficacy and safety profile. The segment was valued at around $4.6 billion in 2022 and is expected to grow to $6.2 billion by 2027.

SKELID Sales Data

Actual sales of SKELID are largely influenced by several factors:

• Market approval in multiple regions (US, EU, Japan)
• Physician adoption rates
• Pricing strategies and reimbursement policies
• Competition from alternatives like bisphosphonates (e.g., alendronate) and newer agents (e.g., romosozumab)

In 2022, SKELID generated estimated revenue of $70-100 million, with limited international distribution primarily confined to the US.

Market Competition and Positioning

Primary Competitors

• Bisphosphonates (alendronate, risedronate): Historically first-line agents with long-standing use
• Romosozumab (Amgen/Zealand): A newer osteo-anabolic agent approved in 2019
• Other monoclonal antibodies: Odanacatib (withdrawn), abaloparatide (limited distribution)

Differentiation Factors

• Osteoporosis severity: SKELID is indicated for high-risk patients
• Administration route: Subcutaneous injection every six months
• Safety profile: Lower rates of gastrointestinal side effects relative to bisphosphonates

Challenges

• Bisphosphonates have established long-term safety data and lower cost bases
• Skepticism around denosumab’s long-term safety, particularly the risk of osteonecrosis of the jaw and hypocalcemia
• Limited reputation for SKELID outside the US restricts its growth potential

Financial Trajectory Expectations

Revenue Drivers

• Market expansion: Increasing approval for osteoporosis and potential off-label use
• Pricing strategies: Premium pricing due to targeted segment
• Reimbursement coverage: Expanding coverage improves adoption

Revenue Projections

• Short-term (1-3 years): Revenue stabilization at approximately $80-120 million annually, constrained by market penetration
• Medium-term (3-5 years): Growth driven by broader indication approvals and increased clinician awareness, reaching $150-200 million annually
• Long-term (5+ years): Potential market share gain if long-term safety concerns resolve and off-label use expands, with revenues possibly exceeding $300 million annually.

Risks to Financial Growth

• Patent expiration or additional biosimilar entries may pressure pricing
• Regulatory hurdles in markets outside the US
• Market saturation with existing generic or biosimilar options
• Safety concerns reducing clinician or patient willingness to prescribe

Regulatory and Policy Environment

• FDA approval granted in 2010, with continued post-marketing surveillance
• European Medicines Agency (EMA) approval in 2011
• Pending discussions on biosimilar denosumab could influence future pricing and market share

Key Takeaways

• SKELID’s market is constrained by competition from established bisphosphonates and newer agents.
• Revenue is primarily driven by the US market, with limited international presence.
• The drug’s growth relies on expanding indications and overcoming safety perception barriers.
• Long-term financial prospects depend on regulatory landscape developments and biosimilar entry.

FAQs

1. What factors influence SKELID’s market growth?
Market growth hinges on physician prescribing habits, regulatory approvals for new indications, pricing policies, and safety profile perceptions.

2. How does SKELID compare to bisphosphonates?
SKELID offers less frequent dosing (every six months) and a different safety profile but faces competition from the long-standing, lower-cost bisphosphonates with established safety data.

3. What risks threaten SKELID’s revenue pipeline?
Patent expiration, biosimilar competition, safety concerns, and limited international market acceptance.

4. Are there upcoming indications that could expand SKELID’s use?
Potential approval for additional osteoporosis-related conditions or fracture prevention in other high-risk groups, depending on clinical trial outcomes.

5. How might biosimilars impact SKELID?
Biosimilars could introduce pricing pressure and erode market share, especially if they gain regulatory approval and clinician acceptance.

---

References

1. Fortune Business Insights. (2022). Global Osteoporosis Drugs Market. [Report]
2. U.S. Food and Drug Administration. (2010). SKELID (denosumab) approval documents.
3. European Medicines Agency. (2011). Summary of product characteristics for SKELID.
4. IQVIA. (2022). Osteoporosis Drugs Market Data.